Lilly, Incyte Trial for Covid-19 Treatment With Baricitinib Sees Positive Results
September 17 2020 - 2:21PM
Dow Jones News
By Chris Wack
Eli Lilly and Co. and Incyte Corp. said initial data emerging
from the Adaptive Covid-19 Treatment Trial sponsored by the
National Institute of Allergy and Infectious Diseases showed
positive results.
ACTT-2 included more than 1,000 patients and began on May 8 to
assess the efficacy and safety of a 4-mg dose of baricitinib plus
remdesivir versus remdesivir in hospitalized patients with
Covid-19.
The companies said baricitinib in combination with remdesivir
met the primary endpoint of reduction of time to recovery in
comparison with remdesivir.
Study investigators noted a one-day reduction in median recovery
time for the overall patient population treated with baricitinib in
combination with remdesivir versus those treated with remdesivir.
The study also met a key secondary endpoint comparing patient
outcomes at Day 15 using an ordinal eight-point scale ranging from
fully recovered to death.
Lilly said it plans to discuss the potential for emergency use
authorization with the U.S. Food and Drug Administration and to
explore similar measures with other regulatory agencies, including
Health Canada, for baricitinib as a treatment of hospitalized
patients with Covid-19. If authorized for use in Canada, Lilly will
propose that baricitinib be available through commercial channels
and will work with hospitals and governments to ensure patient
access.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 17, 2020 14:06 ET (18:06 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024